<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<html lang="en">
<head>
<title>TRANSAVE :: Patients</title>
	<meta name="description" content="TK">
	<meta name="copyright" content="Copyright (c) 2006 TRANSAVE">
	<meta name="author" content="Kyle Hamilton">

    <link href="stylesheet.css" rel="stylesheet" type="text/css">
</head>
<body  onload="MM_preloadImages('images/nav_aboutus_over.gif','images/nav_technology_over.gif','images/nav_products_over.gif','images/nav_invRelations_over.gif','images/nav_news_over.gif','images/nav_partnering_over.gif','images/nav_contact_over.gif')">
<div id="wrap">
	<div id="header"><h1><img src="images/logo.gif" alt="logo"  /></h1>
	</div>
	<div id="nav">
		<!--#include file="includes/nav.html" -->
  </div>
	<div id="main">
		<table width="100%" cellpadding="0" cellspacing="0" >
	  <tr>
	    <td align="left" valign="top"><img src="images/tlc.gif" width="8" height="8" /></td>
	    <td align="left" valign="top" class="grayBgxt" ></td>
	    <td><img src="images/trc.gif" width="8" height="8" /></td>
	  </tr>
	  <tr>
	    <td class="grayBgyl">&nbsp;</td>
	    <td>
			<ol class="circle"><li>Cystic Fibrosis</li></ol>
			<p>The Sustained release Lipid Inhalation Targeting (SLIT™) technology offers the potential ability to attain a prolonged therapeutic effect of amikacin in the lung by sustained release. The benefits of  taking SLIT™ Amikacin by inhalation are that it permits high drug levels at the site of disease with low exposure to other organs, provides biofilm penetration, and requires less frequent dosing.</p>
			<p>Transave is currently conducting Phase I/IIa trials in Europe to test SLIT™ Amikacin for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. The company plans to file an IND and initiate Phase II trials in the United States and Europe 2007. In addition, SLIT™ Amikacin is being developed under Orphan Drug status in the United States and Europe, which upon approval, offers market exclusivity for seven and ten years, respectively.</p>
			<ol class="circle"><li>Osteosarcoma metastatic to the lung</li></ol>
			<p><b>Title:</b>Phase Ib/IIa Study of SLIT™ Cisplatin by Inhalation in the Treatment of Patients with Relapsed/Progressive Osteosarcoma Metastatic to the Lung</p>
			<p>Osteosarcoma, preferentially metastasizes to the lung. The presence of lung metastases has a major impact on the prognosis of patients with osteosarcoma. Upon surgical removal of the tumor in the lung, new pulmonary metastases often recur within months suggesting micro-metastatic disease resistant to systemic chemotherapy.</p>
			<p>The Sustained release Lipid Inhalation Targeting (SLIT™) technology offers the potential ability to attain a prolonged therapeutic effect of cisplatin in the lung by sustained release. The ability to administer SLIT™ Cisplatin by inhalation directly to the lung permits high drug levels at the site of disease with low systemic exposure.</p>
			<p><b>The two current clinical study sites are located in New York, New York:</b></p>
			<ul>
      	<li>The Albert Einstein College of Medicine Montefiore Medical Center</li>
        <li>Memorial Sloan Kettering Cancer Center</li>
			</ul>
      <p>For patients wishing to participate in the osteosarcoma clinical trial, please go to <a href="http://www.clinicaltrials.gov/ct/show/NCT00102531?order=1">http://www.clinicaltrials.gov/ct/show/NCT00102531?order=1</a></p> 
			<p>Or contact <a href="mailto:clinical_affairs@transaveinc.com">clinical_affairs@transaveinc.com</a></p>
			<p>Cancer patients seeking travel assistance to participate in clinical trials or receive treatment not available in their home area, contact Corporate Angel Network or <a href="mailto:clinical_affairs@transaveinc.com">clinical_affairs@transaveinc.com</a></p>
			<ol class="circle"><li>Bronchoalveolar carcinoma</li></ol>
			<p>Transave is currently conducting a Phase II trial to test SLIT™ Cisplatin in the treatment of bronchoalveolar carcinoma (a subset of non-small cell lung cancer).</p>
			<p>For more information on current and future trials, please contact: <a href="mailto:clinical_affairs@transaveinc.com">clinical_affairs@transaveinc.com</a></p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p>&nbsp;</p>
			</td>
	    <td class="grayBgyr"></td>
	  </tr>
	  <tr>
	    <td><img src="images/blc.gif" width="8" height="8" /></td>
	    <td class="grayBgxb"></td>
	    <td><img src="images/brc.gif" width="8" height="8" /></td>
	    </tr>
	  </table>
	</div>
  <div id="sidebar">
  
  <table width="100%" cellpadding="0" cellspacing="0" >
	  <tr>
	    <td align="left" valign="top"><img src="images/tlc.gif" width="8" height="8" /></td>
	    <td align="left" valign="top" class="grayBgxt" ></td>
	    <td align="right"><img src="images/trc.gif" width="8" height="8" /></td>
	  </tr>
	  <tr>
	    <td class="grayBgyl"></td>
	    <td>
  
		<p>&quot;Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Fusce pulvinar lobortis purus. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec semper ipsum et urna. Ut consequat neque vitae felis. Suspendisse dapibus, magna quis pulvinar laoreet, dolor neque lacinia arcu, et luctus mi erat vestibulum sem.&quot;</p>
		</td>
	    <td class="grayBgyr"></td>
	  </tr>
	  <tr>
	    <td colspan="3"><img src="images/girl_with_bubbles.gif" width="350" height="254" /></td>
      </tr>
	  <tr>
	    <td class="grayBgyl"></td>
	    <td>
  
		<p>&nbsp;</p>
		</td>
	    <td class="grayBgyr"></td>
	  </tr>
	  
	  <tr>
	    <td><img src="images/blc.gif" width="8" height="8" /></td>
	    <td class="grayBgxb"></td>
	    <td align="right"><img src="images/brc.gif" width="8" height="8" /></td>
	    </tr>
	  </table>
		
  </div>
	<div id="footer">
		<p align="center"><!--#include file="includes/footer.html" --></p>
	</div>
</div>
</body>
</html>